Noxopharm Ltd. · ASX:NOX
Noxopharm — Investor Presentation (October 2017)
37 slides from Noxopharm's investor presentation, Oct 19, 2017
Slide 1: October 19th Open Briefing Corporate Presentation
19 October 2017 Sydney, Australia For personal use only ASX Limited ASX: NOX 20 Bridge Street SYDNEY 2000 Noxopharm Limited ABN 50 608 966 123 October 19th Open Briefing Corporate Presentation Registered Office: Suite 1 Level 6 Noxopharm Limited (ASX:NOX) is pleased to provide the market 50 Queen St
Slide 2: Forward Looking Statements
Forward Looking Statements This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “shoul
Slide 3: For personal use only
For personal use only ASX: NOX 1
Slide 4: NOX: Unique opportunities
Noxopharm NOX: Unique opportunities For personal use only NOX66 Idronoxil Non-oncology v Kills all forms of cancer cells ? Monotherapy Idronoxil-C Ability to deliver IV drugs across v Sensitises to Blood-Brain and ? Chemo-sensitiser Blood-Nerve chemotherapy barriers Idronoxil-C v Sensitises to ? Rad
Slide 5: Radiotherapy vs chemotherapy
Noxopharm For personal use only Radiotherapy vs chemotherapy • more effective way of killing cancer cells • more likely to be curative (early tumours) • shorter treatment course (2 vs 20 weeks) • fewer side-effects • tumours within the 1 patient can have different mutations .. problem for targeted 3
Slide 6: Limitations of radiotherapy: indiscriminate action
Noxopharm Limitations of radiotherapy For personal use only 1. Action is indiscriminate Radiation dose needs Radiation to be limited in order does NOT to avoid excessive discriminate killing of healthy tissue between a plus cancer cell limit to amount of total and a Radiation physically radiation bo
Slide 7: Limitations of radiotherapy: metastatic cancer too extensive
Noxopharm Limitations of radiotherapy For personal use only 2. Metastatic cancer too extensive Metastatic cancer can be associated with multiple (dozens / 100s) small tumours known as micro-metastases. Tumours seen on scans can be just ‘tip of the iceberg’. A few larger tumours can be irradiated. Bu
Slide 8: NOX66 first-in-class radiosensitiser
Noxopharm NOX66 For personal use only FIRST-IN-CLASS RADIOSENSITISER SENSITISES ONLY CANCER CELLS (NOT HEALTHY CELLS) TO RADIATION DOES NOT CREATE ANY MORE DAMAGE…IT WORKS BY BLOCKING ABILITY OF THE CELL TO REPAIR THE EXISTING DAMAGE ALLOWS THE DOSE OF RADIATION TO BE LOWERED TO MORE TOLERABLE LEVEL
Slide 9: NOX66 Clinical Program: DARRT
Noxopharm NOX66 CLINICAL PROGRAM For personal use only DARRT Program [Direct and Abscopal Response to RadioTherapy] 7
Slide 10: Direct sensitisation
Noxopharm DARRT Program For personal use only direct sensitisation + NOX66 Radio-sensitive cells die Most or all cancer cells die Tumor exposed to radiation Less radio-sensitive survive 8
Slide 11: Direct sensitisation with NOX66
Noxopharm DARRT Program For personal use only direct sensitisation + NOX66 Shrinkage of irradiated Complete resolution of Direct radio-sensitising effect Direct radio-sensitising Palliative radiotherapy tumours irradiated tumours effect 9
Slide 12: Abscopal response
Noxopharm DARRT Program For personal use only Abscopal response + NOX66 Individual tumor exposed to Normal response: Abscopal response: radiation • Irradiated tumor dies • Irradiated tumor dies • Non-irradiated tumors unaffected • Non-irradiated tumors also die 10
Slide 13: Abscopal response with NOX66
Noxopharm DARRT Program For personal use only Abscopal response + + NOX66 NOX66 + Complete resolution of Complete resolution of Palliative radiotherapy Direct radio-sensitising irradiated tumours effect Direct radio-sensitising effect non-irradiated tumours 11
Slide 14: Abscopal response: rare case reports
Noxopharm DARRT Program For personal use only Extremely rare 8 case reports ABSCOPAL Complete/permanent response RESPONSE Range of tumour types 12
Slide 15: Mechanism unknown: theories
Noxopharm DARRT Program For personal use only Mechanism - unknown Theory 1 Theory 2 Immune response: ABSCOPAL Epigenetic effect: Release of tumour RESPONSE Release of miRNA antigens from from dying cancer injured cancer cells cells initiate suicide initiates vaccine-like genes in non- effect irradia
Slide 16: Phase 1b proof-of-concept Clinical Program
Noxopharm DARRT For personal use only Phase 1b ‘proof-of-concept’ Clinical Program NOX66 + External beam radiotherapy responses: 1 Ø Direct effect only Ø Direct effect + abscopal effect 2 NOX66 + External beam radiotherapy + chemotherapy in event of direct response only 3 NOX66 + Brachytherapy (inte
Slide 17: Phase 1b proof-of-concept Clinical Program: study design
Noxopharm DARRT For personal use only 1 Phase 1b ‘proof-of-concept’ Clinical Program 1-3 lesions Late-stage irradiated. cancer. (Palliative dose) No treatment options At least 1 lesion NOT irradiated 2-5 measurable lesions NOX66 daily for 10-14 days • Measure: response (RECIST) in measurable lesions
Slide 18: Primary proof-of-concept study
Noxopharm DARRT Primary proof-of-concept study 1 For personal use only Q4 2017 Q1 2018 Q2 2018 Q3 2018 Q4 2018 NOX66-002A: Prostate Cancer 24 Patients, 5 Centres (Australia) Study Review of design. Interim Approvals data Site recruitment. Phase 3 registration study. Multi-national. 16
Slide 19: Solid cancers
Noxopharm DARRT Solid cancers 1 For personal use only Q4 2017 Q1 2018 Q2 2018 Q3 2018 Q4 2018 Open Label Common & Less Common Cancers 30 patients, 8-10 Centres (Aust, NZ, Europe) Open Label Rare Cancers up to 200 patients, 50 centres, multi-national 17
Slide 20: DARRT Phase 1b: common, less common and rare cancers
DARRT For personal use only 1 Common, Phase Less 1b Clinical Common and Rare Cancers Program Common Cancers – incidence >12 in 100,000 eg. colorectal; lung; breast; prostate; melanoma Less Common Cancers – incidence 6-12 in 100,000 eg. brain, liver, thyroid, head and neck; stomach; pancreas; kidney;
Slide 21: NOX66 + Radiotherapy + chemotherapy
Noxopharm DARRT 2 For personal use only NOX66 + Radiotherapy + chemotherapy v Phase 1b/2a study QUESTIONS: v Stage 4 solid cancers v Can NOX66 make carboplatin-resistant tumors v NOX66 + carboplatin respond to carboplatin? v 16 patients v Can chemo dose be reduced to non-toxic levels? Oct Dec 1x NOX
Slide 22: Prostate cancer brachytherapy
Noxopharm DARRT Prostate cancer 3 For personal use only brachytherapy Radioactive ligand Attaches to prostate cancer cells 177lutetium isotope Antibody (peptide) against PSMA (prostate specific membrane antigen) 20
Slide 23: Sensitisation of 177lutetium-PSMA-617 brachytherapy
Noxopharm DARRT For personal use only 3 Sensitisation of 177lutetium-PSMA-617 brachytherapy brachytherapy Collective experience in > 200 patients Late-stage prostate cancer cases following failure of standard therapy • About 20% show no meaningful response • About 60% show partial response • About 2
Slide 24: LUPIN study
Noxopharm DARRT For personal use only 3 Sensitisation of 177lutetium-PSMA-617 brachytherapy brachytherapy LUPIN (LuPSMA –Idronoxil) Study St Vincent’s Hospital, Sydney • Metastatic castrate-resistant prostate cancer following standard therapy • PSMA-expressing cancer (majority of cases) Objectives:
Slide 25: Key metrics
Noxopharm Key metrics ……….. For personal use only A$ 0.80 Shares outstanding 107M : 60M free; 47M escrowed (Sept 2018) 0.60 Other 22.5M options ($0.30) (2021) 0.40 0.20 Market Cap (18.8.2017) $37M 0.00 Aug/2016 Nov/2016 Feb/2017 May/2017 Aug/2017 IPO price 20 cents Last traded 43 cents CEO Cash posi
Slide 26: Key Messages
Noxopharm For personal use only Key Messages WE EXPECT TO KNOW BY END OF 2017 OF THE SUCCESS OF OUR MISSION WE AIM TO BE IN A REGISTRATION STUDY BY END OF 2018 WE AIM TO HAVE MARKETING APPROVAL BY 2022 A SUCCESSFUL OUTCOME IS A MAJOR SHARE OF THE $100 BILLION ONCOLOGY DRUG MARKET REALISTIC POTENTIAL
Slide 27: Nyrada: A Noxopharm subsidiary
For personal use only A Noxopharm subsidiary US-based (New York) Non-oncology drug development q Neurodegenerative diseases q Hypercholesterolaemia 25
Slide 28: NOX66… why it works
NOX66… why it works For personal use only LIPROSE ✚ (Lipid Protective Shield) è idronoxil-c Idronoxil • Protects drug from inactivation • Time in body extended >10x • Crosses blood-brain barrier (pre-clinical) 26
Slide 29: LIPROSE technology and protective barriers
Brain, spinal cord and peripheral nerves have protective barrier For personal use only LIPROSE technology enables certain chemical classes of 27 drugs to cross this barrier
Slide 30: Two underlying pathologies of neurodegeneration
Two underlying pathologies of neurodegeneration For personal use only Excitotoxicity Inflammation Death of healthy brain Interference to normal cells from over- Excitotoxicity nerve cell function by stimulation by & inflammation. inflammation neurotransmitters Associated with dumped from dying demye
Slide 31: NYX-104: An inhibitor of excitotoxicity
NYX-104 An inhibitor of excitotoxicity For personal use only Repeated concussion Chronic traumatic encephalopathy Stroke 29
Slide 32: NYX-205: An inhibitor of neuro-inflammation
NYX-205 An inhibitor of neuro-inflammation For personal use only Targeting peripheral neuropathy Incidence in US estimated at 20 million: • Diabetes • Alcohol abuse • Chemotherapy 30
Slide 33: NYX-330: An inhibitor of LDL cholesterol
NYX-330 An inhibitor of LDL cholesterol For personal use only LDL cholesterol associated with increased risk of heart attack and stroke US$40 billion ‘statin’ drug market now largely generic PCSK9 identified as superior drug target as statin drugs achieve target LDL-C levels in only 1 in 3 people PC
Slide 34: NYX-330: PCSK9 binding site
NYX-330 An inhibitor of LDL cholesterol For personal use only Australian chemists identify suitable binding site on PCSK9 for attachment of small molecule. NYX-330 effectively blocks binding of PCSK9 to LDL-cholesterol. Appropriate drug-like behaviour in mice. Pre-clinical program underway. 32
Slide 35: For NOX shareholders, Nyrada means
For personal use only For NOX shareholders, Nyrada means: Development of 2 drug assets in a non-dilutive way Acquisition of a 3rd drug asset without dilution Allowing NOX to focus on its considerable oncology opportunity Value-adding to early-stage assets that otherwise would remain undeveloped Owni
Slide 36: Disclaimer
For personal use only Disclaimer • This presentation has been prepared by Noxopharm Limited a company listed as [ASX:NOX] (NOX or the Company). It should not be considered as an offer or invitation to subscribe for or purchase any shares in NOX or as an inducement to make an offer or invitation to s
Slide 37: Contact
For personal use only Contact Dr Graham Kelly Chief Executive Officer graham.kelly@noxopharm.com 35